Electra_Logo

Electra Therapeutics presents first clinical data from ongoing Phase 1b study of ELA026 for treatment of secondary hemophagocytic lymphohistiocytosis (sHLH)

ELA026 showed favorable safety and achieved overall response rate (ORR) of 70% in sHLH patients Majority of enrolled patients were in difficult-to-treat subtypes of sHLH associated with malignancies and relapsed/refractory disease SOUTH SAN FRANCISCO, CA, December 11, 2023 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases […]

Electra Therapeutics Appoints Kathy Dong, PharmD, MBA, as President and Chief Executive Officer

Company expands board of directors and appoints Matthew Fust as independent director Building on positive clinical results for its lead antibody candidate, Electra is positioned to expand therapeutic opportunities in immunological diseases and cancer SOUTH SAN FRANCISCO, CA, December 11, 2023 – Electra Therapeutics, a clinical stage biotechnology company developing antibody therapies against novel targets […]

Electra Therapeutics to Present Clinical Data for ELA026 at the American Society of Hematology (ASH) 2023 Annual Meeting

Company to reveal first clinical data from Phase 1b study of ELA026, its lead product candidate for life-threatening inflammatory disease, secondary hemophagocytic lymphohistiocytosis (sHLH) SOUTH SAN FRANCISCO, CA, November 2, 2023 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets, announced today that the company will present the initial […]

Electra Therapeutics highlights ELA026 Phase 1b study in sHLH and presents preclinical data at ASH Annual Meeting

Ongoing Phase 1b study progressing in US and EU for ELA026 in sHLH, a life-threatening inflammatory disease Preclinical data demonstrate ELA026 proof-of-mechanism of SIRP targeting and depletion of pathological immune cells that drive sHLH Company also presents results of sHLH natural history study SOUTH SAN FRANCISCO, CA, December 12, 2022 – Electra Therapeutics, Inc., a clinical […]

Electra Therapeutics to Highlight ELA026 in Three Presentations at the American Society of Hematology (ASH) 2022 Annual Meeting

Company’s lead product candidate, ELA026, is in a clinical study for a life-threatening inflammatory disease, secondary hemophagocytic lymphohistiocytosis (sHLH) SOUTH SAN FRANCISCO, CA, November 3, 2022 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies that target signal regulatory proteins (SIRP), announced today that the company will present three posters related to […]

Electra Therapeutics announces $84 million Series B financing and unveils its novel SIRP targeted therapies for immunological diseases and cancer

Company’s first-in-class approach to targeting of signal regulatory proteins (SIRP) enables specific depletion of pathological immune cells Financing enables lead product candidate, ELA026, to reach clinical proof of concept in the inflammatory disease sHLH, expansion of ELA026 into other indications, and advancement of two additional programs towards the clinic SOUTH SAN FRANCISCO, CA, February 16, […]